Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi has signed a deal with AI-driven drug discovery firm Atomwise that could be worth up to $1.2 billion if all of the five undisclosed targets in the…
Sanofi SA and Atomwise Inc. have entered a research collaboration and license agreement under which Sanofi will leverage Atomwise's AtomNet artificial…
Numerion Labs, formerly known as Atomwise, publishes APEX virtual-screening research with NVIDIA; confirms rebrand and refocus on internal pipeline.
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi signed a $1.2B biobucks AI drug-discovery research collaboration with Atomwise. Sanofi paid $20M upfront with up to $1B in research, development and sales milestones plus tiered royalties. Atomwise's AtomNet platform applies deep learning to a 3-trillion-compound library to identify small-molecule candidates against up to five undisclosed targets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Atomwise Inc. (this deal) | 2022 | $1.0B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Multiple (undisclosed) deals